{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:32:41Z","timestamp":1786516361507,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00641-x","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:08:42Z","timestamp":1786514922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nilotinib-loaded hydroxy propyl \u03b2-cyclodextrin nanosponges for improved oral bioavailability in chronic myeloid leukemia therapy"],"prefix":"10.1007","volume":"34","author":[{"given":"Bhagya Buela","family":"Gudipalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"AV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Kakarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Datta Maroti","family":"Pawde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash Kumar","family":"G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaykumar","family":"Thummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakravarthi","family":"Guntupalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buchi N.","family":"Nalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona Muthu","family":"madaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasi Viswanadh","family":"matte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"2","key":"641_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","volume":"6","author":"S Hoelder","year":"2012","unstructured":"Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012;6(2):155\u201376.","journal-title":"Mol Oncol"},{"issue":"6","key":"641_CR2","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1021\/acs.molpharmaceut.3c01086","volume":"21","author":"P Dhamija","year":"2024","unstructured":"Dhamija P, Mehata AK, Tamang R, Bonlawar J, Vaishali, Malik AK, et al. Redox-sensitive poly (lactic-co-glycolic acid) nanoparticles of palbociclib: development, ultrasound\/photoacoustic imaging, and smart breast cancer therapy. Mol Pharm. 2024;21(6):2713\u201326.","journal-title":"Mol Pharm"},{"key":"641_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","volume":"7","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193.","journal-title":"Front Mol Biosci"},{"issue":"sup2","key":"641_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21691401.2018.1457039","volume":"46","author":"A Dadwal","year":"2018","unstructured":"Dadwal A, Baldi A, Kumar Narang R. Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup2):295\u2013305.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"1","key":"641_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"S Senapati","year":"2018","unstructured":"Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3(1):7.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"641_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.seminhematol.2023.06.002","volume":"60","author":"A Nasser","year":"2023","unstructured":"Nasser A, Iddy H. Setting up a network of comprehensive care for patients with chronic myeloid leukemia: Lessons learned from Tanzania. Semin Hematol. 2023;60(4):204\u20138.","journal-title":"Semin Hematol"},{"issue":"11","key":"641_CR7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL DeRemer","year":"2008","unstructured":"DeRemer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30(11):1956\u201375.","journal-title":"Clin Ther"},{"issue":"4","key":"641_CR8","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1021\/mp2001022","volume":"8","author":"S Shukla","year":"2011","unstructured":"Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu C-P, et al. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol pharm. 2011;8(4):1292\u2013302.","journal-title":"Mol pharm"},{"issue":"2","key":"641_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2010","unstructured":"Tanaka C, Yin O, Sethuraman V, Smith T, Wang X, Grouss K, et al. Clinical pharmacokinetics of the BCR\u2013ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther. 2010;87(2):197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"641_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","volume":"41","author":"M Herbrink","year":"2015","unstructured":"Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412\u201322.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"641_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/2405461508666230817101938","volume":"9","author":"M Tamminana","year":"2024","unstructured":"Tamminana M, Ravi Kumar BV. Formulation design and characterization of nilotinib polymeric nanoparticles by nanoprecipitation technique for the improved drug solubility and dissolution rate. Curr Nanomater. 2024;9(3):252\u201365.","journal-title":"Curr Nanomater"},{"key":"641_CR12","doi-asserted-by":"publisher","first-page":"122627","DOI":"10.1016\/j.ijpharm.2023.122627","volume":"634","author":"P \u0160alam\u00fanov\u00e1","year":"2023","unstructured":"\u0160alam\u00fanov\u00e1 P, Krej\u010d\u00ed T, Ry\u0161\u00e1nek P, Salo\u0148 I, Kroupov\u00e1 J, Hubatov\u00e1-Vackov\u00e1 A, et al. Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os. Int J Pharm. 2023;634:122627.","journal-title":"Int J Pharm"},{"issue":"10","key":"641_CR13","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s13346-023-01334-7","volume":"13","author":"M Chougule","year":"2023","unstructured":"Chougule M, Sirvi A, Saini V, Kashyap M, Sangamwar AT. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid\u2013base neutralization approach. Drug Deliv Transl Res. 2023;13(10):2503\u201319.","journal-title":"Drug Deliv Transl Res"},{"key":"641_CR14","doi-asserted-by":"publisher","first-page":"103038","DOI":"10.1016\/j.jddst.2021.103038","volume":"68","author":"S Zhu","year":"2022","unstructured":"Zhu S, Yu R, Qian G, Deng L. A supersaturating drug delivery system to enhance the oral bioavailability of nilotinib. J Drug Deliv Sci Technol. 2022;68:103038.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"641_CR15","doi-asserted-by":"publisher","first-page":"e06652","DOI":"10.1016\/j.heliyon.2021.e06652","volume":"7","author":"M Zhalechin","year":"2021","unstructured":"Zhalechin M, Dehaghi SM, Najafi M, Moghimi A. Magnetic polymeric core-shell as a carrier for gradual release in-vitro test drug delivery. Heliyon. 2021;7(5):e06652.","journal-title":"Heliyon"},{"issue":"3","key":"641_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/03639045.2020.1730398","volume":"46","author":"A Zakkula","year":"2020","unstructured":"Zakkula A, Gabani BB, Jairam RK, Kiran V, Todmal U, Mullangi R. Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability. Drug Dev Ind Pharm. 2020;46(3):498\u2013504.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"641_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijpharm.2017.07.010","volume":"529","author":"M Herbrink","year":"2017","unstructured":"Herbrink M, Schellens JH, Beijnen JH, Nuijen B. Improving the solubility of nilotinib through novel spray-dried solid dispersions. Int J Pharm. 2017;529(1\u20132):294\u2013302.","journal-title":"Int J Pharm"},{"key":"641_CR18","doi-asserted-by":"crossref","unstructured":"Viswanathan P, Muralidaran Y, Ragavan G. In: Ecaterina A, Alexandru MG, editors. Challenges in oral drug delivery: A nano-based strategy to overcome. Nanostructures for oral medicine: Elsevier; 2017. pp. 173\u2013201.","DOI":"10.1016\/B978-0-323-47720-8.00008-0"},{"key":"641_CR19","doi-asserted-by":"crossref","unstructured":"Bagade O, Sampathi S. Restoration and Sustenance of Nano Drug Delivery Systems: Potential, Challenges, and Limitations. In: Kulkarni S, Haghi AK, Manaker S, editors. Biosystems, biomedical & drug delivery systems: Characterization, restoration and optimization. Springer; 2024. pp. 105\u201339.","DOI":"10.1007\/978-981-97-2596-0_6"},{"key":"641_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.carbpol.2017.05.086","volume":"173","author":"AP Sherje","year":"2017","unstructured":"Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: A critical review. Carbohydr Polym. 2017;173:37\u201349.","journal-title":"Carbohydr Polym"},{"issue":"1","key":"641_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.18433\/J3K308","volume":"15","author":"S Selvamuthukumar","year":"2012","unstructured":"Selvamuthukumar S, Anandam S, Nanosponges. A novel class of drug delivery system-review. J Pharm Pharm Sci. 2012;15(1):103\u201311.","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"641_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ph16010019","volume":"16","author":"MK Anwer","year":"2022","unstructured":"Anwer MK, Ahmed MM, Aldawsari MF, Iqbal M, Kumar V. Preparation and evaluation of diosmin-loaded diphenylcarbonate-cross-linked cyclodextrin nanosponges for breast cancer therapy. Pharmaceuticals. 2022;16(1):19.","journal-title":"Pharmaceuticals"},{"key":"641_CR23","doi-asserted-by":"crossref","unstructured":"Aldawsari MF, Alhowail AH, Anwer MK, Ahmed MM. Development of diphenyl carbonate-crosslinked cyclodextrin based nanosponges for oral delivery of baricitinib: formulation, characterization and pharmacokinetic studies. Int J Nanomed. 2023;18:2239\u201351.","DOI":"10.2147\/IJN.S405534"},{"issue":"3","key":"641_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1208\/s12249-009-9264-8","volume":"10","author":"VR Yadav","year":"2009","unstructured":"Yadav VR, Suresh S, Devi K, Yadav S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech. 2009;10(3):752\u201362.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"641_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s43094-024-00680-8","volume":"10","author":"KSC Reddy","year":"2024","unstructured":"Reddy KSC, Bhikshapathi D. Design and optimization of DPC-crosslinked HP\u03b2CD nanosponges for entrectinib oral delivery: formulation, characterization, and pharmacokinetic studies. Future J Pharm Sci. 2024;10(1):101.","journal-title":"Future J Pharm Sci"},{"issue":"4","key":"641_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","volume":"16","author":"LX Yu","year":"2014","unstructured":"Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju G, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771\u201383.","journal-title":"AAPS J"},{"issue":"57","key":"641_CR27","doi-asserted-by":"publisher","first-page":"34869","DOI":"10.1039\/D0RA06611G","volume":"10","author":"A Moin","year":"2020","unstructured":"Moin A, Roohi NF, Rizvi SMD, Ashraf SA, Siddiqui AJ, Patel M, et al. Design and formulation of polymeric nanosponge tablets with enhanced solubility for combination therapy. RSC Adv. 2020;10(57):34869\u201384.","journal-title":"RSC Adv"},{"key":"641_CR28","doi-asserted-by":"publisher","first-page":"123746","DOI":"10.1016\/j.ijpharm.2023.123746","volume":"650","author":"US Bagul","year":"2024","unstructured":"Bagul US, Nazirkar MV, Mane AK, Khot SV, Tagalpallewar AA, Kokare CR. Fabrication of architectonic nanosponges for intraocular delivery of Brinzolamide: An insight into QbD driven optimization, in vitro characterization, and pharmacodynamics. Int J Pharm. 2024;650:123746.","journal-title":"Int J Pharm"},{"key":"641_CR29","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.jddst.2021.102684","volume":"65","author":"PP Prabhu","year":"2021","unstructured":"Prabhu PP, Gujaran TV, Mehta CH, Suresh A, Koteshwara K, Pai KG, Nayak UY. Development of lapatinib nanosponges for enhancing bioavailability. J Drug Deliv Sci Technol. 2021;65:102684.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"8","key":"641_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1208\/s12249-019-1524-7","volume":"20","author":"N Rangaraj","year":"2019","unstructured":"Rangaraj N, Pailla SR, Chowta P, Sampathi S. Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability. AAPS PharmSciTech. 2019;20(8):326.","journal-title":"AAPS PharmSciTech"},{"key":"641_CR31","doi-asserted-by":"publisher","first-page":"123787","DOI":"10.1016\/j.ijpharm.2024.123787","volume":"651","author":"N Rajana","year":"2024","unstructured":"Rajana N, Chary PS, Bhavana V, Deshmukh R, Dukka K, Sharma A, Mehra NK. Targeted delivery and apoptosis induction of CDK-4\/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells. Int J Pharm. 2024;651:123787.","journal-title":"Int J Pharm"},{"key":"641_CR32","doi-asserted-by":"publisher","first-page":"133287","DOI":"10.1016\/j.colsurfa.2024.133287","volume":"686","author":"C Singh","year":"2024","unstructured":"Singh C, Mehata AK, Viswanadh MK, Tiwari P, Saini R, Singh SK, et al. Chitosan film of thiolated TPGS-modified Au-Ag nanoparticles for combating multidrug-resistant bacteria. Colloids Surf A: Physicochem Eng Asp. 2024;686:133287.","journal-title":"Colloids Surf A: Physicochem Eng Asp"},{"issue":"2","key":"641_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.pharep.2014.09.010","volume":"67","author":"P Neerati","year":"2015","unstructured":"Neerati P, Bedada SK. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacol Rep. 2015;67(2):339\u201344.","journal-title":"Pharmacol Rep"},{"issue":"9","key":"641_CR34","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3390\/pharmaceutics14091947","volume":"14","author":"S Sampathi","year":"2022","unstructured":"Sampathi S, Prajapati S, Junnuthula V, Dyawanapelly S. Pharmacokinetics and anti-diabetic studies of gliclazide nanosuspension. Pharmaceutics. 2022;14(9):1947.","journal-title":"Pharmaceutics"},{"issue":"9","key":"641_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jsps.2021.07.019","volume":"29","author":"AF Alghaith","year":"2021","unstructured":"Alghaith AF, Mahrous GM, Zidan DE, Alhakamy NA, Alamoudi AJ, Radwan AA. Preparation, characterization, dissolution, and permeation of flibanserin\u2009\u2013\u20092-HP-\u03b2-cyclodextrin inclusion complexes. Saudi Pharm J. 2021;29(9):963\u201375.","journal-title":"Saudi Pharm J"},{"key":"641_CR36","doi-asserted-by":"crossref","unstructured":"Kshirsagar RV, Rajewar SR, Kokil SS, Viswanadh MK, Patrakar RG, Pawde DM. Integrating the Quality-by-Design (QbD) Approach in the Development of Febuxostat-loaded Proniosomal Gel for Topical Delivery. Nano Biomed Eng. 2024;16(4):625\u2212637.","DOI":"10.26599\/NBE.2024.9290101"},{"key":"641_CR37","doi-asserted-by":"publisher","first-page":"118617","DOI":"10.1016\/j.carbpol.2021.118617","volume":"274","author":"MK Viswanadh","year":"2021","unstructured":"Viswanadh MK, Mehata AK, Sharma V, Priya V, Varshney N, Mahto SK, Muthu MS. Bioadhesive chitosan nanoparticles: Dual targeting and pharmacokinetic aspects for advanced lung cancer treatment. Carbohydr Polym. 2021;274:118617.","journal-title":"Carbohydr Polym"},{"key":"641_CR38","doi-asserted-by":"publisher","first-page":"124458","DOI":"10.1016\/j.molliq.2024.124458","volume":"399","author":"P Paul","year":"2024","unstructured":"Paul P, Gupta U, Kumar R, Munagalasetty S, Padhy HP, Nair R, et al. Fabrication of \u03b2-cyclodextrin and 2-hydroxypropyl-\u03b2-cyclodextrin inclusion complexes of Palbociclib: Physicochemical characterization, solubility enhancement, in-silico studies, in vitro assessment in MDA-MB-231 cell line. J Mol Liq. 2024;399:124458.","journal-title":"J Mol Liq"},{"issue":"24","key":"641_CR39","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2217\/nnm-2020-0167","volume":"15","author":"MK Viswanadh","year":"2020","unstructured":"Viswanadh MK, Vikas, Jha A, Reddy Adena SK, Mehata AK, Priya V, et al. Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. Nanomed (Lond). 2020;15(24):2345\u201367.","journal-title":"Nanomed (Lond)"},{"issue":"2","key":"641_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.xphs.2020.10.026","volume":"110","author":"T Loftsson","year":"2021","unstructured":"Loftsson T. Cyclodextrins in parenteral formulations. J Pharm Sci. 2021;110(2):654\u201364.","journal-title":"J Pharm Sci"},{"issue":"1","key":"641_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.22159\/ijap.2024v16i1.48817","volume":"16","author":"S Sampathi","year":"2024","unstructured":"Sampathi S, Maddukuri S, Ramavath R, Dodoala S, Kuchana V. Modified cyclodextrin-based thermosensitive in situ gel for voriconazole ocular delivery against fungal keratitis. Int J Appl Pharm. 2024;16(1):150\u201360.","journal-title":"Int J Appl Pharm"},{"issue":"6","key":"641_CR42","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3390\/ijms25063527","volume":"25","author":"B Pyrak","year":"2024","unstructured":"Pyrak B, Rogacka-Pyrak K, Gubica T, Szeleszczuk \u0141. Exploring cyclodextrin-based nanosponges as drug delivery systems: understanding the physicochemical factors influencing drug loading and release kinetics. Int J Mol Sci. 2024;25(6):3527.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"641_CR43","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/molecules23051161","volume":"23","author":"P Saokham","year":"2018","unstructured":"Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of Cyclodextrins and drug\/cyclodextrin complexes. Molecules. 2018;23(5):1161.","journal-title":"Molecules"},{"issue":"4","key":"641_CR44","first-page":"7492","volume":"17","author":"DM Pawde","year":"2024","unstructured":"Pawde DM, Kokil SS, Rajewar SR, Viswanadh MK, Bonde GV, Kshirsagar RV. Integration of quality by design (QbD) principles in the engineering of an oral delivery nanosystem loaded with fenofibrate. Int J Pharm Sci Nanotechnol. 2024;17(4):7492\u2013503.","journal-title":"Int J Pharm Sci Nanotechnol"},{"key":"641_CR45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.carbpol.2018.05.011","volume":"195","author":"C Mendes","year":"2018","unstructured":"Mendes C, Meirelles GC, Barp CG, Assreuy J, Silva MA, Ponchel G. Cyclodextrin based nanosponge of norfloxacin: Intestinal permeation enhancement and improved antibacterial activity. Carbohydr Polym. 2018;195:586\u201392.","journal-title":"Carbohydr Polym"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00641-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:08:43Z","timestamp":1786514923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00641-x","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were carried out by the \"Guidelines for Care and Use of Laboratory Animals,\" the protocols were officially approved by the Institutional Animal Ethics Committee (IAEC) under protocol ID 1447\/PO\/Re\/S\/11\/CPCSEA-95\/A","order":1,"name":"Ethics","label":"Ethical studies approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}